TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
+$0.14 today
- Market cap
- $87.31M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
Volume 0.19M
Average 0.85M
HURA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
TuHURA Biosciences, Inc.NASDAQ: HURA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $2.3M rose 13.9% year over year, ahead of the -47.4% change in trailing-twelve-month selling, general & admin. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +95.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.3M+247.1% QoQ
- Last fiscal yearDec 2025
- $7.58M+95.8% YoY
- LTMMar 2026
- $3.55M-47.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +13.9% | -100.0% | -113.9 pp |
| 1 year | +95.8% | -100.0% | -195.8 pp |
| 3-year CAGR | +11.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 7.58M USD
- Year-over-year change
- +95.8%
- 4-year CAGR
- +0.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.58M | +95.8% |
| FY2024 | 2024-12-31 | 3.87M | -32.4% |
| FY2023 | 2023-12-31 | 5.73M | +5.7% |
| FY2022 | 2022-12-31 | 5.43M | -27.2% |
| FY2021 | 2021-12-31 | 7.45M | — |
Selling, General & Admin vs competitors
How HURA compares with its peers on the latest reported figures
- HURA's LTM Mar 2026 selling, general & admin of $3.55M is the lowest of the 9 companies compared; the peer median is $28.45M.
- Its year-over-year change of -47.4% is the lowest of 9, against a peer median of -16.9%.
- Over three fiscal years its annual growth of +11.8% compares with a peer median of -9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.46B | +48531.9% | -28.7% | — | |
| LTM Mar 2026 | $45.53M | -35.6% | -12.4% | 36.8% | |
| LTM Mar 2026 | $40.57M | -24.5% | -6.8% | 269.8% | |
| LTM Mar 2026 | $35.34M | -27.5% | -17.7% | 3080.9% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $21.57M | +8.6% | +44.6% | 180.0% |
| LTM Mar 2026 | $19.24M | -21.8% | -16.6% | 35.1% | |
| LTM Mar 2026 | $18.46M | -7.7% | +13.7% | — | |
| LTM Mar 2026 | $10.32M | -12.0% | -7.1% | — | |
| LTM Mar 2026 | $3.55M | -47.4% | +11.8% | — | |
| Peer median (excluding HURA) | $28.45M | -16.9% | -9.8% | 180.0% | |
Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 60K | 60K | 55K | 0 | 0 |
| Gross Profit | (60K) | (60K) | (55K) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 15.17M | 9.31M | 2.66M | 13.34M | 20.53M |
| Selling, General & Admin | 7.45M | 5.43M | 5.73M | 3.87M | 7.58M |
| Operating Expenses | 22.62M | 14.74M | 8.4M | 17.65M | 31.8M |
| Depreciation & Amortization | 60K | 60K | 55K | 116.71K | 71.27K |
| EBITDA | (21.97M) | (14.59M) | (8.27M) | (17.43M) | (29.36M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (22.68M) | (14.8M) | (8.45M) | (17.65M) | (31.8M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 57.35K | 89.67K | 361.63K | 136.23K |
| Interest Expense | 629.29K | 0 | 18.69K | 4.14M | 625.28K |
| Other Income / Expenses | 21K | 147K | 131K | (4.03M) | 1.74M |
| Income Before Tax | (22.66M) | (14.65M) | (8.32M) | (21.68M) | (30.06M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (22.66M) | (14.65M) | (8.32M) | (21.68M) | (30.06M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (903.04) | (324.48) | (11.29) | (1.21) | (0.63) |
| EPS (Diluted) | (903.04) | (324.48) | (11.29) | (1.21) | (0.63) |
| Weighted Avg Shares | 27.83K | 46.29K | 752.91K | 18.66M | 47.93M |
| Weighted Avg Shares (Diluted) | 27.83K | 46.29K | 752.91K | 18.66M | 47.93M |
TuHURA Biosciences, Inc.
NASDAQ:HURA
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.